fig1

Promises and pitfalls of targeted agents in chronic lymphocytic leukemia

Figure 1. Target agents in chronic lymphocytic leukemia. AKT: v-akt murine thymoma viral oncogene; PI3K: phosphatidylinositol 3-kinase; SYK: spleen tyrosine kinase; BTK: bruton tyrosine kinase; BCR: B-cell receptor; BCL2: B-cell lymphoma 2; CLL: chronic lymphocytic leukemia; BAK: BCL2 homologous antagonist killer; BAX: BCL2 associated X; BH3: BCL2 homology domain 3

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/